Mankind Pharma Share Price in Focus; CGST Appeals Authority Drops ₹1.02 Crore Penalty

Mankind Pharma Limited has received an order from the appellate authority in Meerut granting relief in a long-standing tax matter, as per an exchange filing. The decision eliminates a penalty of ₹1,02,05,688 that had earlier been imposed on the company. 

Appeal Outcome and Background 

The order, dated January 28, 2026 and received by the company on February 25, 2026, relates to proceedings covering financial years 2017–18 to 2020–21. The appellate authority set aside the earlier penalty demand that arose from an order issued in December 2024. 

With the penalty now dropped, the company is no longer required to account for the earlier demand amounting to ₹1,02,05,688. The matter had been under review following the company’s appeal against the initial decision. 

Mankind Pharma informed stock exchanges about the development, confirming receipt of the appellate order and the closure of the penalty demand. 

About Mankind Pharma  

Mankind Pharma Ltd is one of India’s leading pharmaceutical manufacturers, established in 1991 and headquartered in New Delhi. The company produces a broad portfolio of prescription medicines and consumer healthcare products across key therapeutic areas such as anti-infectives, gastrointestinal, cardiovascular and dermatology.  

It has built a strong presence in both urban and rural markets through an extensive distribution network, with well-known brands including Manforce and Prega News contributing significantly to its domestic growth. 

Read More: Hindalco Share Price in Focus; AluChem Acquisition Put on Hold Due to US Shutdown! 

Mankind Pharma Share Price Performance  

As of 27 February 2026, at 9:25 AM, Mankind Pharma Limited share price is trading at ₹2,268.70 per share, a decline of 0.48% from the previous closing price. Over the past month, the stock has gained by 8.34%. 

Conclusion 

The decision brings clarity to the tax issue pertaining to earlier financial years and removes a monetary liability of over ₹1 crore from the company’s books, strengthening its financial position going forward. 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.  

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.